Dapagliflozin
- Product NDC
- 70518-4816
- 11-digit product format
- 705184816
- Labeler code
- 70518
- Product ID
- 70518-4816_606843cc-c18b-0999-e063-6394a90a7aaf
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Dapagliflozin
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- REMEDYREPACK INC.
- Application
- ANDA211478
- Marketing category
- ANDA
- Marketing start
- 2026-11-16
- Substance
- DAPAGLIFLOZIN
- Active strength
- 5 mg/1
- Pharmacologic classes
- Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211478-001 | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | |
| A211478-002 | DAPAGLIFLOZIN | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A211478-001 | AB |
| A211478-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A211478-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A211478-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A211478-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A211478-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A211478-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A211478-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A211478-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A211478-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211478-001 | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211478-002 | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | 2026-04-06 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A211478-001 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A211478-002 | AB | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A211478-001 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211478-002 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A211478-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211478-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A211478-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211478-002 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211478-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211478-002 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Dapagliflozin
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| DAPAGLIFLOZIN | 5 mg/1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dapagliflozin | DAPAGLIFLOZIN | Novadoz Pharmaceuticals LLC | 107b4d25-4764-42b7-80e3-9aaff20865ed | 2026-06-17 | Warnings, Adverse reactions | 211478 ANDA211478 |
| Dapagliflozin | DAPAGLIFLOZIN | AvKARE | 52a778e7-6044-2049-e063-6294a90aa0b7 | 2026-05-27 | Warnings, Adverse reactions | 211478 ANDA211478 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 70518-4816-0 | 70518481600 | 30 TABLET, FILM COATED in 1 BLISTER PACK (70518-4816-0) | 2026-11-16 | No | No | Current |